RIO DE JANEIRO, BRAZIL - U.S. laboratory Moderna on Thursday, August 19, began testing an HIV vaccine based on messenger RNA (mRNA) technology, the same type as the anti-Covid vaccine.
Phase 1 human trials, formally published in the U.S. National Institutes of Health (NIH) registry, will involve 56 people aged 18 to 50 who are not virus carriers. Like any early trial, the study aims to verify the immune response and its safety for use.
It will be administered in two versions: half of the group will be given two equal doses of the mRNA-1644 immunizer, and . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here